Form 4: Aquestive Therapeutics CEO Daniel Barber Reports Stock Transactions

Daniel Barber, CEO of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options related to vesting and tax obligations.

Summary

• On March 7, 2025, Daniel Barber, the President and CEO of Aquestive Therapeutics, acquired 272,000 shares of common stock.
• These shares are represented by restricted stock vesting in three annual installments: 25% on the first, 25% on the second, and 50% on the third.
• Also on March 7, 2025, 29,307 shares were disposed of to cover tax obligations related to vesting Restricted Stock Units (RSUs) at a price of $2.65 per share.
• On March 9, 2025, an additional 53,998 shares were disposed of for tax obligations at $2.65 per share.
• Barber also acquired 408,000 non-qualified stock options with an exercise price of $2.65, vesting in three annual installments similar to the restricted stock.
• Following these transactions, Barber directly owns 1,015,173 shares of common stock and 408,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are related to standard executive compensation practices (vesting and tax obligations) and do not indicate a significant change in the CEO's confidence in the company.

Positives

• The acquisition of 272,000 shares of restricted stock by the CEO demonstrates a continued investment in the company's future.
• The vesting schedule of the restricted stock and stock options incentivizes long-term performance.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the CEO's direct holdings.

Risks

• Future tax obligations related to vesting equity could lead to further disposal of shares by the CEO.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Insider transactions are a normal part of executive compensation in publicly traded companies like Aquestive Therapeutics.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies such as Xeris Biopharma and Collegium Pharmaceutical.
• The vesting schedules for the restricted stock and stock options are also standard practice to align executive incentives with long-term shareholder value, similar to equity grants at companies like BioDelivery Sciences International.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the CEO's stake in the company.
• Employees may be indirectly impacted by the CEO's actions, as they reflect the leadership's commitment to the company's success.

Key Dates